BVI’s FINEVISION® HP Gains FDA Approval, Ushering in a New Era of Advanced Trifocal IOLs for U.S. PatientsWALTHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone reinforces BVI’s leadership in premium IOLs and expands advanced vision solutions for U.S. patients.
BVI Unveils Virtuoso® – A Novel Dual-Function Surgical Platform for Cataract and Vitreoretinal ProceduresWALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures.
BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative glaucoma surgical system, Leos™ (Laser Endoscopy Ophthalmic System)
BVI significantly expands its presence in Spain and Portugal acquiring Medical MixWALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BVI, one of the fastest-growing, diversified surgical ophthalmic businesses in the world, announced the acquisition of Medical Mix, a company specializing in the supply of medical devices for ophthalmic surgery across Spain and Portugal.
BVI Expands IOL Capacity with New State of the Art Facility in BelgiumWALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium. This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership.
BVI launches FINEVISION HP, a novel hydrophobic trifocal IOL based on the FINE optical technology platform, in JapanWALTHAM, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- BVI, one of the fastest growing surgical ophthalmic businesses in the world, is thrilled to announce the official launch of FINEVISION HP in Japan. The FINEVISION HP hydrophobic and glistening free trifocal IOL represents a significant breakthrough in trifocal technology as the first trifocal platform to offer cataract patients high quality vision across all distances.
BVI Announces Complete Enrollment of FINEVISION® HP IDE Clinical StudyWALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens (IOL), FINEVISION® HP.
